A Phase 2 interventional study of Isatuximab and Dexamethasone or equivalent in Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, sponsored by Sanofi. Terminated at 41 sites in 16 countries. Open to participants aged 28 Days to 17 Years. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Sanofi — none open to participants now, none under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Sanofi.
Among the 11 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Sanofi, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2019, is one of 5 in phase 2, and was the 10th registered.
2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →None of the 11 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Sanofi is open now. The open studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, anywhere →
Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.
This study: 28 Days to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7
First in 1997; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is above the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 64 across the 10 interventional studies. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Evaluate the anti-leukemic activity of isatuximab in combination with standard chemotherapies in pediatric participants of ages 28 days to less than 18 years with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML)
Secondary Objectives:
The study included:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm includes participants from 3 cohorts: AML, T-ALL and B-ALL.; AML: Weekly dosing of isatuximab with induction chemotherapy. The therapy may be repeated one more cycle; ALL: (Includes T-ALL and B-ALL) Weekly dosing of isatuximab with induction chemotherapy, then biweekly dosing of isatuximab with consolidation chemotherapy.
Drug: Isatuximab · Drug: Dexamethasone or equivalent · Drug: Fludarabine · Drug: Cytarabine · Drug: Liposomal daunorubicin · Drug: Daunorubicin (nonliposomal) · Drug: Idarubicin · Drug: Filgrastim or equivalent · Drug: Mitoxantrone · Drug: Doxorubicin · Drug: Vincristine · Drug: Pegaspargase (PEG) Asparaginase · Drug: Cyclophosphamide · Drug: Etoposide · Drug: Methotrexate · Drug: L - Asparginase · Drug: Hydroxyurea · Drug: L - Asparaginase (Erwinase)
Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: Intravenous
Also known as: SAR650984, Sarclisa
Pharmaceutical form: Solution for injection or tablet Route of administration: Intravenous or oral
Pharmaceutical form: Solution for injection Route of administration: Intravenous
Pharmaceutical form: Solution for injection Route of administration: Intravenous
Pharmaceutical form: Solution for injection Route of administration: Intravenous
Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Pharmaceutical form: Solution for injection Route of administration: Intravenous
Pharmaceutical form: Solution for injection Route of administration: Intravenous
Pharmaceutical form: Solution for injection Route of administration: Intravenous
Pharmaceutical form: Solution for injection Route of administration: Intravenous
Pharmaceutical form: Solution for injection Route of administration: Intravenous
Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Pharmaceutical form: Solution for injection Route of administration: Intravenous
Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Pharmaceutical form: Solution for injection Route of administration: Intramuscular
Pharmaceutical form: Solution for injection Route of administration: PO
Pharmaceutical form: Solution for injection Route of administration: Intramuscular
Percentage of Participants With Complete Response (CR) Rate
The complete response rate (CR + CRi \[complete response with incomplete peripheral recovery\]) was defined as the percentage of participants achieving complete response (CR + CRi) assessed by the investigator per National Comprehensive Cancer Network (NCCN) guidelines version 1.2018 criteria. CR was defined as \<5% blasts in a bone marrow aspirate (BMA) with spicules; no circulating blasts (ALL)/no blasts with Auer rods (AML) or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement (ALL), trilineage hematopoiesis (ALL); Absolute neutrophil count (ANC) \>=1000/microliter (mcL); platelets \>100000/mcL; red blood cell transfusion independence. If the physician documented transfusion dependency related to study treatment and not to the participant's underlying disease, CRi was reported. CRi met the same criteria as for CR, except neutrophils and/or platelets recovery (ANC \<1000/mcL or platelets \<100000/mcL).
Time frame: From enrollment until the primary analysis completion date of 12 Sep 2022; the median duration of exposure was approximately 7 weeks
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as an AE which occurred after the first dose of study treatment administration until the last dose plus 30 days, or until the start of hematological recovery period or a new anti-leukemia/lymphoma therapy, whichever occurred first.
Time frame: From the time of the first treatment administration (Day 1) up to 30 days after the last treatment (maximum duration of exposure of 13.1 weeks for B-ALL cohort, 10.7 weeks for T-ALL cohort and 7.1 weeks for AML cohort)
Number of Participants With Infusion Reactions (IRs)
An IR was an AE related to isatuximab typically with onset within 24 hours from the start of the isatuximab infusion and was reported by the investigator.
Time frame: From the time of the first treatment administration (Day 1) up to 30 days after the last treatment (maximum duration of exposure of 13.1 weeks for B-ALL cohort, 10.7 weeks for T-ALL cohort and 7.1 weeks for AML cohort)
B-ALL and T-ALL: Area Under the Concentration Time Curve (AUC) of Isatuximab
Plasma samples were collected at specified timepoints to determine the AUC of isatuximab.
Time frame: From Week 0 to Week 1, Week 0 to Week 5, and Week 0 to Week 10
AML: AUC of Isatuximab
Plasma samples were collected at specified timepoints to determine the AUC of isatuximab.
Time frame: From Week 0 to Week 1, Week 0 to Week 3, and Week 0 to Week 8
B-ALL and T-ALL: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)
Plasma samples were collected at specified timepoints to determine the Ctrough of isatuximab.
Time frame: Cycle 1 Day 8, Cycle 1 Day 15, Cycle 1 Day 22, Cycle 1 Day 29, Cycle 2 Day 43, Cycle 2 Day 57
AML: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)
Plasma samples were collected at specified timepoints to determine the Ctrough of isatuximab.
Time frame: Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 2 Day 15
B-ALL and T-ALL: Concentrations at the End of Infusion (Ceoi) of Isatuximab
Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.
Time frame: At end of infusion on Cycle 1 Days 1 and 29
AML: Ceoi of Isatuximab
Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.
Time frame: At end of infusion on Cycle 1 Days 1 and 15
Number of Participants With Negative Minimal Residual Disease (MRD)
MRD assessment was performed centrally by next generation sequencing using clonoSEQ and T-cell receptor assays for B-ALL and T-ALL cohorts respectively. It was performed by flow cytometry for AML cohort. Number of participants with CR or CRi who achieved negative MRD in bone marrow and blood was analyzed. In AML indication, peripheral blood tissue is not representative of the tumor burden and cannot be used to assess MRD.
Time frame: From screening until the study completion date, approximately 45 months
Overall Response Rate (ORR)
ORR:Percentage of participants with CR/CRi or partial response (PR) for blood and bone marrow disease based on NCCN guideline. CR: \<5% blasts in BMA with spicules; no circulating blasts (ALL)/no blasts with Auer rods (AML) or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement (ALL), trilineage hematopoiesis (ALL);ANC \>=1000/mcL; platelets \>100000/mcL; RBC transfusion independence. If the physician documented transfusion dependency related to study treatment;not to participant's underlying disease, CRi was reported. CRi met the same criteria as CR, except neutrophils and/or platelets recovery (ANC \<1000/mcL or platelets \<100000/mcL). PR: \>50% decrease in the sum of the product of the greatest perpendicular diameters of the mediastinal enlargement. For participants with a previous positive positron emission tomography (PET) scan, a post-treatment PET was to be positive in at least 1 previously involved site.
Time frame: From enrollment until the primary analysis completion date of 12 Sep 2022; the median duration of exposure was approximately 7 weeks
Overall Survival (OS)
Overall survival was defined as the time interval from the date of first study treatment administration to death from any cause. It was estimated using the Kaplan-Meier method. Confidence interval (CI) for Kaplan-Meier estimates were calculated with log-log transformation of survival function and methods of Brookmeyer and Crowley.
Time frame: From first study treatment administration up to death due to any cause, a maximum of 45 months
Event-Free Survival (EFS)
EFS was defined as the time interval from the date of first study treatment administration to the date of the first of: completion or going off protocol induction/consolidation therapy without CR, relapse from CR, or death due to any cause, whichever occurred first. It was estimated using the Kaplan-Meier method. CI for Kaplan-Meier estimates are calculated with log-log transformation of survival function and methods of Brookmeyer and Crowley.
Time frame: From study treatment administration up to the date of first documented disease progression or death due to any cause, a maximum of 45 months
Duration of Response (DoR)
Duration of response was defined as the time from the date of the first response to the date of first disease progression or death from any cause, whichever happens first. It was estimated using the Kaplan-Meier method. CI for Kaplan-Meier estimates are calculated with log-log transformation of survival function and methods of Brookmeyer and Crowley.
Time frame: From first documented response up to the date of first documented disease progression or death due to any cause, a maximum of 45 months
Cluster of Differentiation (CD)38 Receptor Density
Blood samples were collected to assess CD38 receptor density as a predictive biomarker. It was assessed across complete responders and non-complete responders. The Antibody Binding Capacity (ABC) was calculated using the following equation: ABC = 10\^(Logarithm(Mean Fluorescence Intensity)\*a+b) where "a" was the slope and "b" was the Y-intercept of the calibration curve equation. Specific and absolute quantitative values (specific antibody-binding capacity \[sABC\]) of binding of the selected antibodies were calculated after subtraction of the negative isotypic immunoglobulin G (IgG) control.
Time frame: Pre-dose on Day 1
CD38 Receptor Occupancy
Blood samples were collected to assess CD38 receptor occupancy as a pharmacodynamics marker. It was assessed across complete responders and non-complete responders. Multicolor flow cytometry assay was validated for CD38 receptor occupancy (CD38RO) quantification, based on the use of two murine monoclonal antibodies (MAbs), one competing with SAR650984 to determine the number of free CD38 receptors (MAb1) and one recognizing a different binding epitope on CD38 to measure the total number of receptors (MAb2) at the cell surface of the cancer cells. Cells were tagged with either MAb1 (Tube #1) or MAb2 (Tube #2). The percentage RO was calculated using the following equation: % CD38RO = \[(sABC MAb2 - sABC MAb1)/sABC MAb2\] X 100.
Time frame: Pre-dose on Day 15
This Phase II, open-label, single-arm study was conducted in 3 separate cohorts at 41 investigational sites in 16 countries. A total of 67 participants were enrolled between 06 Aug 2019 and 08 Jun 2022.
| Milestone | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) | Acute Myeloid Leukemia (AML) |
|---|---|---|---|
| Started | 27 | 13 | 27 |
| Completed | 19 | 7 | 20 |
| Not completed | 8 | 6 | 7 |
| Withdrew: Adverse event, not related to coronavirus disease-2019 (covid-19) | 3 | 2 | 3 |
| Withdrew: Progressive disease | 5 | 3 | 4 |
| Withdrew: Other, not related to covid-19 | 0 | 1 | 0 |
The complete response rate (CR + CRi \[complete response with incomplete peripheral recovery\]) was defined as the percentage of participants achieving complete response (CR + CRi) assessed by the investigator per National Comprehensive Cancer Network (NCCN) guidelines version 1.2018 criteria. CR was defined as \<5% blasts in a bone marrow aspirate (BMA) with spicules; no circulating blasts (ALL)/no blasts with Auer rods (AML) or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement (ALL), trilineage hematopoiesis (ALL); Absolute neutrophil count (ANC) \>=1000/microliter (mcL); platelets \>100000/mcL; red blood cell transfusion independence. If the physician documented transfusion dependency related to study treatment and not to the participant's underlying disease, CRi was reported. CRi met the same criteria as for CR, except neutrophils and/or platelets recovery (ANC \<1000/mcL or platelets \<100000/mcL).
| percentage of participants | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) | Acute Myeloid Leukemia (AML) |
|---|---|---|---|
| Percentage of Participants With Complete Response (CR) Rate | 52.0 | 45.5 | 60.9 |
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as an AE which occurred after the first dose of study treatment administration until the last dose plus 30 days, or until the start of hematological recovery period or a new anti-leukemia/lymphoma therapy, whichever occurred first.
| Participants | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) | Acute Myeloid Leukemia (AML) |
|---|---|---|---|
| Any TEAE | 27 | 13 | 26 |
| Any TESAE | 19 | 12 | 17 |
An IR was an AE related to isatuximab typically with onset within 24 hours from the start of the isatuximab infusion and was reported by the investigator.
| Participants | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) | Acute Myeloid Leukemia (AML) |
|---|---|---|---|
| Number of Participants With Infusion Reactions (IRs) | 9 | 5 | 15 |
Plasma samples were collected at specified timepoints to determine the AUC of isatuximab.
| mg*hour (h)/Liter (L) | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) |
|---|---|---|
| Week 0 to Week 1 | 31703 ± 10048 | 29057 ± 8294 |
| Week 0 to Week 5 | 299071 ± 127581 | 289167 ± 93095 |
| Week 0 to Week 10 | 582686 ± 316749 | 540375 ± 233411 |
Plasma samples were collected at specified timepoints to determine the AUC of isatuximab.
| mg*h/L | Acute Myeloid Leukemia (AML) |
|---|---|
| Week 0 to Week 1 | 28592 ± 6858 |
| Week 0 to Week 3 | 130862 ± 40827 |
| Week 0 to Week 8 | 291962 ± 112222 |
Plasma samples were collected at specified timepoints to determine the Ctrough of isatuximab.
| microgram/milliliter (mcg/mL) | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) |
|---|---|---|
| Cycle 1: Day 8 | 114 ± 45.7 | 127 ± 49.9 |
| Cycle 1: Day 15 | 272 ± 118 | 263 ± 103 |
| Cycle 1: Day 22 | 388 ± 163 | 323 ± 206 |
| Cycle 1: Day 29 | 475 ± 174 | 426 ± 209 |
| Cycle 2: Day 43 | 504 ± 296 | 357 ± NA |
| Cycle 2: Day 57 | 531 ± 224 | 478 ± 261 |
Plasma samples were collected at specified timepoints to determine the Ctrough of isatuximab.
| mcg/mL | Acute Myeloid Leukemia (AML) |
|---|---|
| Cycle 1: Day 8 | 126 ± 41.0 |
| Cycle 1: Day 15 | 217 ± 60.6 |
| Cycle 2: Day 1 | 115 ± 94.2 |
| Cycle 2: Day 15 | 420 ± 205 |
Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.
| mcg/mL | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) |
|---|---|---|
| Cycle 1: Day 1 | 452 ± 344 | 259 ± 120 |
| Cycle 1: Day 29 | 835 ± 366 | 745 ± 330 |
Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.
| mcg/mL | Acute Myeloid Leukemia (AML) |
|---|---|
| Cycle 1: Day 1 | 363 ± 110 |
| Cycle 1: Day 15 | 562 ± 176 |
MRD assessment was performed centrally by next generation sequencing using clonoSEQ and T-cell receptor assays for B-ALL and T-ALL cohorts respectively. It was performed by flow cytometry for AML cohort. Number of participants with CR or CRi who achieved negative MRD in bone marrow and blood was analyzed. In AML indication, peripheral blood tissue is not representative of the tumor burden and cannot be used to assess MRD.
| Participants | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) | Acute Myeloid Leukemia (AML) |
|---|---|---|---|
| Blood, 10^-6 | 3 | 1 | — |
| Bone marrow, 10^-6 | 0 | 2 | 0 |
| Bone marrow, 10^-3 | — | — | 0 |
ORR:Percentage of participants with CR/CRi or partial response (PR) for blood and bone marrow disease based on NCCN guideline. CR: \<5% blasts in BMA with spicules; no circulating blasts (ALL)/no blasts with Auer rods (AML) or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement (ALL), trilineage hematopoiesis (ALL);ANC \>=1000/mcL; platelets \>100000/mcL; RBC transfusion independence. If the physician documented transfusion dependency related to study treatment;not to participant's underlying disease, CRi was reported. CRi met the same criteria as CR, except neutrophils and/or platelets recovery (ANC \<1000/mcL or platelets \<100000/mcL). PR: \>50% decrease in the sum of the product of the greatest perpendicular diameters of the mediastinal enlargement. For participants with a previous positive positron emission tomography (PET) scan, a post-treatment PET was to be positive in at least 1 previously involved site.
| percentage of participants | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) | Acute Myeloid Leukemia (AML) |
|---|---|---|---|
| Overall Response Rate (ORR) | 52.0 (37.5 to 66.2) | 54.5 (31.8 to 75.9) | 65.2 (49.7 to 78.6) |
Overall survival was defined as the time interval from the date of first study treatment administration to death from any cause. It was estimated using the Kaplan-Meier method. Confidence interval (CI) for Kaplan-Meier estimates were calculated with log-log transformation of survival function and methods of Brookmeyer and Crowley.
| months | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) | Acute Myeloid Leukemia (AML) |
|---|---|---|---|
| Overall Survival (OS) | 12.09 (3.975 to NA) | 6.85 (2.201 to NA) | 9.40 (5.947 to NA) |
EFS was defined as the time interval from the date of first study treatment administration to the date of the first of: completion or going off protocol induction/consolidation therapy without CR, relapse from CR, or death due to any cause, whichever occurred first. It was estimated using the Kaplan-Meier method. CI for Kaplan-Meier estimates are calculated with log-log transformation of survival function and methods of Brookmeyer and Crowley.
| months | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) | Acute Myeloid Leukemia (AML) |
|---|---|---|---|
| Event-Free Survival (EFS) | 2.23 (1.413 to NA) | 2.14 (1.347 to NA) | 5.65 (1.347 to NA) |
Duration of response was defined as the time from the date of the first response to the date of first disease progression or death from any cause, whichever happens first. It was estimated using the Kaplan-Meier method. CI for Kaplan-Meier estimates are calculated with log-log transformation of survival function and methods of Brookmeyer and Crowley.
| months | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) | Acute Myeloid Leukemia (AML) |
|---|---|---|---|
| Duration of Response (DoR) | 7.26 (NA to NA) | 1.18 (0.887 to NA) | 4.40 (NA to NA) |
Blood samples were collected to assess CD38 receptor density as a predictive biomarker. It was assessed across complete responders and non-complete responders. The Antibody Binding Capacity (ABC) was calculated using the following equation: ABC = 10\^(Logarithm(Mean Fluorescence Intensity)\*a+b) where "a" was the slope and "b" was the Y-intercept of the calibration curve equation. Specific and absolute quantitative values (specific antibody-binding capacity \[sABC\]) of binding of the selected antibodies were calculated after subtraction of the negative isotypic immunoglobulin G (IgG) control.
| sABC | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) | Acute Myeloid Leukemia (AML) |
|---|---|---|---|
| Blood blast cells: CR/CRi | 20345.6 ± 23439.7 | 12780.0 ± 15559.2 | 19502.0 ± 20919.7 |
| Blood blast cells: Non CR/CRi; | 31080.0 ± 2397.1 | 22952.0 ± NA | 9815.0 ± 4203.0 |
| Blood immune cells (Natural Killer [NK] cells): CR/CRi | 13506.2 ± 3018.6 | 22639.0 ± 1796.1 | 11220.3 ± 3764.6 |
| Blood immune cells (NK cells): Non CR/CRi | 16650.0 ± 851.4 | 33859.0 ± NA | 22530.0 ± 685.9 |
Blood samples were collected to assess CD38 receptor occupancy as a pharmacodynamics marker. It was assessed across complete responders and non-complete responders. Multicolor flow cytometry assay was validated for CD38 receptor occupancy (CD38RO) quantification, based on the use of two murine monoclonal antibodies (MAbs), one competing with SAR650984 to determine the number of free CD38 receptors (MAb1) and one recognizing a different binding epitope on CD38 to measure the total number of receptors (MAb2) at the cell surface of the cancer cells. Cells were tagged with either MAb1 (Tube #1) or MAb2 (Tube #2). The percentage RO was calculated using the following equation: % CD38RO = \[(sABC MAb2 - sABC MAb1)/sABC MAb2\] X 100.
| percent receptor occupancy | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) | Acute Myeloid Leukemia (AML) |
|---|---|---|---|
| Blood plasma cells: CR/CRi | — | 40.5 ± 30.4 | — |
| Blood plasma cells: Non CR/CRi; | 44.0 ± NA | 55.0 ± NA | — |
| Blood NK cells: CR/CRi | 55.6 ± 6.9 | 66.7 ± 2.1 | — |
| Blood NK cells: Non CR/CRi | 61.3 ± 3.5 | 70.0 ± NA | — |
Collected over TEAEs were collected from the time of the first treatment administration (Day 1) up to 30 days after the last treatment (maximum duration of exposure of 13.1 weeks for B-ALL cohort, 10.7 weeks for T-ALL cohort and 7.1 weeks for AML cohort). All-cause mortality (Deaths) was collected for the entire study duration, a maximum of 45 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B-cell Acute Lymphoblastic Leukemia (B-ALL) | 17/27 (63%) | 19/27 (70.4%) | 26/27 (96.3%) |
| T-cell Acute Lymphoblastic Leukemia (T-ALL) | 8/13 (61.5%) | 12/13 (92.3%) | 12/13 (92.3%) |
| Acute Myeloid Leukemia (AML) | 18/27 (66.7%) | 17/27 (63%) | 24/27 (88.9%) |
| All Participants | 43/67 (64.2%) | 48/67 (71.6%) | 62/67 (92.5%) |
| Event | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) | Acute Myeloid Leukemia (AML) | All Participants |
|---|---|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 10/27 | 5/13 | 7/27 | 22/67 |
| SepsisInfections and infestations | 1/27 | 2/13 | 1/27 | 4/67 |
| Septic ShockInfections and infestations | 3/27 | 2/13 | 3/27 | 8/67 |
| Device Related InfectionInfections and infestations | 0/27 | 1/13 | 0/27 | 1/67 |
| Disseminated AspergillosisInfections and infestations | 0/27 | 1/13 | 0/27 | 1/67 |
| Escherichia SepsisInfections and infestations | 0/27 | 1/13 | 0/27 | 1/67 |
| Fungal InfectionInfections and infestations | 1/27 | 1/13 | 0/27 | 2/67 |
| Neutropenic SepsisInfections and infestations | 0/27 | 1/13 | 0/27 | 1/67 |
| PeritonitisInfections and infestations | 0/27 | 1/13 | 0/27 | 1/67 |
| Rhinovirus InfectionInfections and infestations | 0/27 | 1/13 | 0/27 | 1/67 |
| Event | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) | Acute Myeloid Leukemia (AML) | All Participants |
|---|---|---|---|---|
| Infusion Related ReactionInjury, poisoning and procedural complications | 8/27 | 4/13 | 14/27 | 26/67 |
| PyrexiaGeneral disorders | 10/27 | 4/13 | 12/27 | 26/67 |
| HypertensionVascular disorders | 0/27 | 5/13 | 3/27 | 8/67 |
| StomatitisGastrointestinal disorders | 10/27 | 4/13 | 8/27 | 22/67 |
| VomitingGastrointestinal disorders | 6/27 | 3/13 | 10/27 | 19/67 |
| HeadacheNervous system disorders | 3/27 | 3/13 | 9/27 | 15/67 |
| NauseaGastrointestinal disorders | 9/27 | 3/13 | 6/27 | 18/67 |
| Decreased AppetiteMetabolism and nutrition disorders | 1/27 | 2/13 | 8/27 | 11/67 |
| DiarrhoeaGastrointestinal disorders | 4/27 | 3/13 | 8/27 | 15/67 |
| ConstipationGastrointestinal disorders | 3/27 | 2/13 | 7/27 | 12/67 |
The All-treated (AT) population consisted of all participants who received at least 1 dose (even incomplete) of study treatment.
| Age, Continuous(years) | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) | Acute Myeloid Leukemia (AML) | Total |
|---|---|---|---|---|
| Mean | 8.22 ± 3.92 | 8.72 ± 4.15 | 9.04 ± 5.41 | 8.65 ± 4.56 |
| Sex: Female, Male(Participants) | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) | Acute Myeloid Leukemia (AML) | Total |
|---|---|---|---|---|
| Female | 10 | 4 | 12 | 26 |
| Male | 17 | 9 | 15 | 41 |
| Race (NIH/OMB)(Participants) | B-cell Acute Lymphoblastic Leukemia (B-ALL) | T-cell Acute Lymphoblastic Leukemia (T-ALL) | Acute Myeloid Leukemia (AML) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 0 | 0 | 3 |
| Asian | 1 | 1 | 4 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 | 4 |
| White | 17 | 7 | 15 | 39 |
| More than one race | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 4 | 4 | 6 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Aug 2019 to primary completion in Sep 2022, 37 months.
Results were first posted in Nov 2023, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Isatuximab
Precursor Cell Lymphoblastic Leukemia-Lymphoma →